Bryce Point Capital LLC Acquires Shares of 28,564 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Bryce Point Capital LLC bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 28,564 shares of the company’s stock, valued at approximately $538,000.

A number of other hedge funds also recently made changes to their positions in NRIX. JPMorgan Chase & Co. increased its holdings in Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock worth $1,531,000 after buying an additional 31,352 shares during the last quarter. Barclays PLC increased its stake in shares of Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after purchasing an additional 56,190 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Nurix Therapeutics by 42.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after purchasing an additional 235,971 shares during the period. FMR LLC lifted its stake in Nurix Therapeutics by 675.9% in the third quarter. FMR LLC now owns 586,902 shares of the company’s stock valued at $13,188,000 after purchasing an additional 511,256 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Nurix Therapeutics by 52.4% during the third quarter. Franklin Resources Inc. now owns 123,101 shares of the company’s stock valued at $2,766,000 after purchasing an additional 42,315 shares during the period.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $10.51 on Friday. The company has a 50-day simple moving average of $15.65 and a two-hundred day simple moving average of $20.04. The firm has a market capitalization of $801.24 million, a PE ratio of -3.64 and a beta of 2.23. Nurix Therapeutics, Inc. has a one year low of $10.21 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the sale, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. The trade was a 6.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on NRIX shares. Leerink Partnrs upgraded Nurix Therapeutics to a “hold” rating in a research note on Monday, March 17th. BTIG Research assumed coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective on the stock. Needham & Company LLC cut their target price on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Leerink Partners began coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They issued a “market perform” rating and a $16.00 price target on the stock. Finally, Stephens reaffirmed an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $30.88.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.